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Abstract
Drug resistance remains a major problem for the treatment of HIV. Resistance can occur due to mutations that were present
before treatment starts or due to mutations that occur during treatment. The relative importance of these two sources is
unknown. Resistance can also be transmitted between patients, but this process is not considered in the current study. We
study three different situations in which HIV drug resistance may evolve: starting triple-drug therapy, treatment with a
single dose of nevirapine and interruption of treatment. For each of these three cases good data are available from
literature, which allows us to estimate the probability that resistance evolves from standing genetic variation. Depending on
the treatment we find probabilities of the evolution of drug resistance due to standing genetic variation between 0 and
39%. For patients who start triple-drug combination therapy, we find that drug resistance evolves from standing genetic
variation in approximately 6% of the patients. We use a population-dynamic and population-genetic model to understand
the observations and to estimate important evolutionary parameters under the assumption that treatment failure is caused
by the fixation of a single drug resistance mutation. We find that both the effective population size of the virus before
treatment, and the fitness of the resistant mutant during treatment, are key-parameters which determine the probability
that resistance evolves from standing genetic variation. Importantly, clinical data indicate that both of these parameters can
be manipulated by the kind of treatment that is used.
Citation: Pennings PS (2012) Standing Genetic Variation and the Evolution of Drug Resistance in HIV. PLoS Comput Biol 8(6): e1002527. doi:10.1371/
journal.pcbi.1002527
Editor: Rob J. De Boer, Utrecht University, Netherlands
Received January 11, 2012; Accepted April 4, 2012; Published June 7, 2012
Copyright:  2012 Pennings. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a long-term fellowship of the Human Frontier Science Program. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pennings@fas.harvard.edu
Introduction
For most HIV patients, treatment with modern antiretroviral
therapy leads to a rapid decline of viral load (VL) of several orders
of magnitude. However, when the virus acquires resistance to one
or more drugs, treatment can fail. It is still an open question
whether the mutations responsible for resistance originate usually
from standing genetic variation (also referred to as pre-existing
mutations or minority variants), or from new mutations which
occur during therapy. In fact, there is no single biological system
for which the relative role of pre-existing and new mutations is well
known [1]. Another important open question is whether multiple
simultaneous mutations are needed for the viral population to be
able to grow during therapy, or whether a single mutation allows
escape. Amongst evolutionary biologists, it is commonly assumed
that therapy with multiple drugs works so well because the virus
needs multiple mutations to escape, which is unlikely to happen.
However, patient data show that patients often fail therapy with a
single resistance mutation [2,3] which suggests that a single
mutation can increase the fitness of the virus to above 1, even
though the virus is still susceptible to two of the drugs in the
treatment. In this scenario, the main benefit of combination
therapy over monotherapy would be that combination therapy
reduces the population size of the virus and therefore the
probability that mutations occur. In this study we will analyze
patient data under the assumption that a single mutation can lead
to virologic failure and thereby propose an alternative view on the
evolution of drug resistance during multi-drug therapy.
We will look at the establishment of drug resistance mutations in
three different situations: (1) when triple-drug therapy (ART) is
started for the first time, (2) when pregnant women are treated
with a single dose of nevirapine (sdNVP) to prevent infection of the
baby during birth and (3) when ART is interrupted and restarted
(an overview of abbreviations is given in table 1). We will argue
that standing genetic variation plays a crucial role in each of these
cases. We find that the probability that resistance mutations
become established in each of these cases can be understood by
using a simple population genetic model.
For readers who are not familiar with HIV, it is important to
know that the genotype-phenotype map for drug resistance in HIV
is very well known. Lists of the important resistance mutations for
each drug are published (e.g., in the International AIDS Society–
USA drug resistance mutations list, [4], so that doctors can
compare the genotype of the virus of a patient before treatment
with this list to decide which drugs to prescribe. The aim of
treatment is to achieve viral suppression. If treatment fails, i.e., the
viral load stays or becomes higher than a predetermined threshold,
such as 50/ml, despite adherence to the regimen, a second
genotypic test will be performed to see whether the virus has
acquired new resistance mutations. Since the second half of the
1990s, treatment is usually with a combination of three drugs,
which are chosen such that mutations which confer resistance
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other two drugs. Soon after its introduction, it became clear that
triple-drug therapy was an enormous success and saved the lives of
many HIV patients [5]. One reason why therapy with three drugs
works better than treatment with one or two drugs is that the rate
at which resistance evolves is slower when patients are treated with
three drugs [6]. It is commonly thought that resistance does not
evolve in patients on triple-drug therapy because it would require
a viral particle to acquire three mutations at the same time.
However, in patients who are treated with triple-drug therapy, it is
often observed that resistance against one of the drugs evolves, at
least initially. Data from several cohort studies in different parts of
the world, such as from Canada [2] and the UK (UK CHIC
cohort study [3], clearly show that in most patients who fail
therapy due to resistance, the virus is resistant against one of the
drugs and almost never against all three. The UK study, for
example, reports that out of 4306 patients who started therapy
between 1996 and 2003, after two years of therapy, 13% have
drug resistance. A majority of the patients with drug resistance
(7%) have resistance against just one of the drugs. Less than half of
the patients (6%) have resistance against more than one class of
drugs and a only small number of patients (1%) have resistance
against 3 classes of drugs, even though all patients of this cohort
were treated with three classes of drugs. These data show that
treatment can fail due to resistance against one of the drugs in a
regimen. In such cases, it may be that the other two drugs cannot
keep the VL completely suppressed, even though they still work.
The viruses that have acquired resistance against two or three
classes of drugs may have acquired these mutations at the same
time or they may have acquired them one by one. For now, we will
assume the latter and focus only on the probability of acquiring the
first drug resistance mutation (DRM).
For many common drugs, especially reverse transcriptase
inhibitors, a single mutation can confer resistance against the
drug and only a small number of mutations is responsible for
resistance in most patients. For example, resistance against the
drug nevirapine is almost always due to one of two amino acid
changes, namely K103N or Y181C in the reverse-transcriptase
gene [7]. Because of the importance of a small number of
mutations, several studies have investigated whether these
mutations are present in untreated patients due to transmitted
drug resistance or due to spontaneous mutation. Recent studies
have used allele-specific PCR and related methods to determine
the frequency of several important mutations in untreated patients.
Low-frequency drug resistance mutations (DRMs), likely due to
spontaneous mutation (and not transmitted from other patients)
were detected in up to 40% of patients (see [8] for an overview).
The detection of drug resistance mutations in untreated patients,
together with the knowledge that a single mutation can confer
resistance against a drug and allow viral escape, suggest that pre-
existing resistance mutations (or standing genetic variation in the
population genetic jargon) may play an important role in the
evolution of drug resistance in HIV.
Throughout the paper, we will assume that a single mutation
can allow viral escape and we focus on the probability that such a
first drug resistance mutation becomes established (i.e., it reaches
such a frequency that it can be expected to become the majority
variant unless treatment is stopped or changed quickly). What
happens after a first mutation has become established, or how fast
such an established mutation wanes in the absence of treatment
are important questions, but they fall outside the scope of this
study. In this paper, ‘‘triple-drug therapy’’ and ART refer to
treatment with two drugs of the class NRTI plus either an NNRTI
or an unboosted PI (for a list of abbreviations in the paper, see
Table 2). The results are likely to be different for other drug
combinations.
Starting therapy
When a patient starts therapy for the first time, one would
expect that there should be a substantial probability that drug
resistance evolves due to pre-existing DRMs. Indeed, recent
studies have shown that the presence of drug resistance mutations
at low frequency (v1%) increases the risk that treatment fails (e.g.,
[9],[10], [7], see [11] for a review). However, the situation is not as
simple as one may hope: even if no pre-existing DRMs can be
detected, resistance mutations may become established quickly,
and even if DRMs are detected, treatment is still successful in the
majority of patients. We will attempt to understand those
observations using population genetic theory. Other authors have
looked at the question of pre-existing DRMs previously (e.g., [12],
Table 1. Abbreviations.
Abbreviation Explanation
VL Viral load, the number of viral particles per ml blood
ART Antiretroviral therapy, here used to mean treatment with
two NRTIs and an NNRTI or an ‘‘unboosted’’ PI
PMTCT Prevention of mother to child transmission
DRM drug resistance mutation
NRTI Drug of class nucleoside reverse transcriptase inhibitor
NNRTI Drug of class non-nucleoside reverse transcriptase
inhibitor
PI Drug of class protease inhibitor, PIs can be used
‘‘unboosted’’ or ‘‘boosted’’ with an additional drug.
NVP Nevirapine, an NNRTI
sdNVP Single dose nevirapine
ZDV Zidovudine, also known as AZT, an NRTI
3TC, DDI, FTC, TDF Drugs of NRTI class
PP Post partem, used here for drugs which are added to
sdNVP right after the mother has given birth
doi:10.1371/journal.pcbi.1002527.t001
Author Summary
For HIV patients who are treated with antiretroviral drugs,
treatment usually works well. However, the virus can, and
sometimes does, become resistant against one or more
drugs. HIV drug resistance results from the acquisition of
specific and well known mutations. It is currently unknown
whether drug resistance mutations usually stem from
standing genetic variation, i.e., they were already present
at low frequency before treatment started, or whether
they tend to occur during treatment. In the current
manuscript, I make use of several large datasets and
evolutionary modeling to estimate the probability that
drug resistance mutations are present before treatment
starts and lead to viral failure. I find that for the most
common type of treatment with a combination of three
drugs, drug resistance evolves from pre-existing mutations
in 6% of the patients. With other types of treatment, this
probability varies from 0 to 39%. I conclude that there is
room for improvement in preventing the evolution of drug
resistance from pre-existing mutations.
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now have a wealth of data available for pre-existing DRMs and
the establishment of drug resistance mutations in HIV patients,
and secondly, we now have a better theoretical framework to
consider the role of standing genetic variation for adaptation [14].
Prevention of mother to child transmission (PMTCT)
Pregnant women in low resource settings are often treated with a
single dose of the non-nucleoside reverse transcriptase inhibitor
neverapine when labor starts. Single dose nevirapine (sdNVP) is the
cheapest and simplest way to reduce the probability of mother-to-
child-transmission, but it is shown to lead to the establishment of
drug resistance mutations in the mothers and the babies. In a meta-
analysis [15], found that, in 7 different studies, on average 44% of
the patients treated with sdNVP had detectable NVP resistance
mutation several weeks after the treatment. The presence of such
mutations makes future treatment of these women harder [16]. To
avoid the establishment of resistance mutations, several alternative
strategies are used in combination with sdNVP. We will use the
same population genetic framework as in the other two cases to try
to understand why sdNVP leads to establishment of resistance
mutations in so many patients, and how this can be avoided. In the
current study we will only focus on the probability that NVP
resistance mutations become established during treatment for
PMTCT. The issue of how these mutations wane and possibly
resurface when treatment is started again is important and
interesting but falls outside the scope of the current paper.
Treatment interruptions
It was long suspected that treatment interruptions lead to drug
resistance. Indeed, cohort studies show that treatment interrup-
tions due to non-adherence are associated with faster accumula-
tion of drug resistance mutations ([17,18,19]. Clear evidence that
treatment interruptions of at least a couple of weeks lead to the
establishment of resistance mutations comes from clinical trials
(e.g., [20,21,22] which were done in a time when it was believed
that treatment interruptions may be beneficial for patients. In
2006 the SMART trial was stopped because treatment interrup-
tions were shown to have a negative effect on patients’ health [23].
However, treatment interruptions still occur, for example, when a
patient is forgetful or is unable to purchase drugs due to financial
or logistic barriers. It is important to understand how treatment
interruptions lead to resistance and whether this effect can be
avoided.
The main idea that currently governs the thinking about
treatment interruptions and resistance is that insufficient drug-
levels allow for replication and, at the same time, select for
resistance (e.g., [24,25,18]. This effect is aggravated when drugs
that are part of combination therapy have very different half-lifes,
so that interrupting combination therapy can result in effective
monotherapy. It is generally believed that this ‘‘tail of monother-
apy’’ is the main reason why treatment interruptions lead to drug
resistance. However, several observations are not compatible with
the ‘‘tail’’ hypothesis. For example, Fox et al ([25]) found no
significant difference in the number of resistance mutations after
simultaneous, ‘‘staggered’’ or ‘‘switched’’ treatment interruptions
in patients from the SMART trial (a ‘‘staggered’’ stop means that
the long half-life drug is interrupted several days before the other
drugs and a ‘‘switched’’ stop means that before interrupting,
patients switch to a regimen with only short half-life drugs). In
addition, the ‘‘tail’’ hypothesis fails to explain why treatment
interruptions increase the risk of resistance in patients on protease
inhibitor-based (PI) regimens which do not have long half-lifes
[26,20,27,28,29,30]. Another explanation is therefore needed to
understand the observed patterns.
When treatment is interrupted, the viral load rapidly increases
until it has reached its original level after approximately four weeks
[31]. Basic population genetics tells us that such population growth
also leads to an increase in the probability that DRMs are present.
When treatment is started again, selection may work on such pre-
existing mutations, which provides a simple explanation for how
treatment interruptions lead to the establishment of resistance
mutations.
In this paper we will attempt to explain the observed patterns by
considering selection on pre-existing variation and selection on
new mutations. It is worth noting here that pre-existing does not
necessarily mean old, such a mutation may have originated just a
day before the start of treatment. Throughout the paper, we use a
mathematical model for adaptation from standing genetic
variation which we developed previously [14] and forward-in-
time, individual-based computer simulations. The model captures
mutation, drift and selection, including changing selection
pressures (due to stopping and starting of therapy) which lead to
changes in population size. Because we only focus on the
establishment of the first drug resistance mutation, we can ignore
epistatic interactions between different drug-resistance mutations
and recombination. In each of the three cases of interest, we use
published data on the percentage of patients with established drug
resistance mutations to estimate important parameter values (for
starting ART or sdNVP) and to predict outcomes (for treatment
interruptions).
Table 2. Parameter values for analytical predictions and
computer simulations.
Parameter Value Explanation
Values roughly based on literature
m 5*1025 Mutation rate to resistant genotype
Nu 2000 Effective population size in
untreated patient
Crel 0.05 Relative cost of mutant in absence
of therapy
FwtART~FwtNVP 0.5 Absolute fitness of wildtype during
therapy
G 200 Number of HIV generations per
year
Values estimated in current study
NART 108 Effective population size in patient
on ART
NLAT 5 Number of activated latent cells in
patient on ART
NZDV 1000 Effective population size in patient
on ZDV monotherapy
Fwtu 1.62 Absolute fitness of wildtype in
absence of therapy (determines
growth rate during treatment
interruption)
Fmu 1.54 Absolute fitness of resistant mutant
in absence of therapy
FmART 1.017 Absolute fitness of resistant mutant
during ART
FmNVP 1.54 Absolute fitness of resistant mutant
during NVP therapy
FmNVP=PP 1.025 Absolute fitness of resistant mutant
during NVP/PP therapy
doi:10.1371/journal.pcbi.1002527.t002
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Model, assumptions and fixation probability of a drug
resistance mutation
The model we use in this paper describes the population
dynamics and population genetics of a panmictic viral population
in a single patient. Details of the model can be found in the
supplementary material. We assume that as long as the patient is
not treated, the viral population will be stable at population size
Nu (u for untreated). Drugs reduce the fitness of the wildtype virus
to below 1 so that the population will shrink. We assume that there
is a large reservoir of latently infected cells of which a fixed
number (NLAT) become activated per generation, so that the virus
can not die out. Drug resistant virus can be created by mutation
and is assumed to be resistant against one of the drugs in the
treatment regimen. If the patient is not taking drugs, the drug
resistant virus is less fit than the wildtype by a factor Crel (relative
cost of the resistant virus), but if the patient is taking drugs, the
resistant virus has a fitness that is higher than 1 (FmARTw1),
whereas the wildtype has a fitness lower than 1 (FwtARTv1). In
reality, there may also be resistance mutations that confer
resistance against one of the drugs, but that do not lead to a
fitness higher than 1. Such mutations will quickly die out and can
safely be ignored in the model. Throughout the paper we focus on
the the processes that allow a first major drug resistance mutation
to become established in the patient. Patients are assumed to be
ART-naive and have no transmitted drug resistance.
Evolutionary biologists have long known that most mutations
will be lost by genetic drift even if they confer a fitness benefit [32].
This is also true for drug resistance mutations (DRMs) in patients
on anti-retroviral therapy, although it is all too often ignored in
drug resistance studies. The clinical relevance of this old result has
recently become very clear. It was found in several studies that
even though low frequency DRMs increase the risk of treatment
failure and establishment of drug resistance, the majority of
patients with detected low frequency DRMs will respond well to
treatment [7]. This result shows that DRMs can die out, even if
they have reached frequencies high enough to be detected. The
reason is probably that most viral particles will not infect any new
cells and produce no new viral particles, even if, on average, they
produce more than 1.
The probability that a DRM becomes established in the patient
depends on the number of copies that are present, the average
number of offspring of the drug resistant particles and the variance
in offspring number. Traditionally, fixation or establishment
probabilities are calculated using the relative fitness difference
between the mutant and the wildtype, but in the case of HIV it is
more useful to use the fitness of the mutant virus to calculate its
establishment probability. The reason is that anti-retroviral
therapy works so well that wildtype fitness may be very low
(much lower than 1). In such case fitness of the mutant may not be
related to the fitness of the wildtype and because the wildtype
cannot grow, the two types do not compete for resources. In other
words, the mutant can occupy a niche that is not occupied by the
wildtype. In those cases, and as long as FmART{1vv1, the
establishment probability of the mutant will be approximately
Pest&
2(FmART{1)
s2 where s2 is the variance in offspring number. In
the simulations and throughout this paper, we use the variance
effective population size, in which case one can assume that s2~1,
so that
Pest&2( FmART{1) ð1Þ
Note that by setting s2~1, we ignore all mutations which occur
in virus which is not part of the effective population size. The
establishment probability of a mutation in a random viral particle
(e.g., when observed in a patient) may be much lower. It is
important to realize that if the establishment probability of a DRM
depends on its absolute fitness, anything that reduces its fitness will
reduce the establishment probability. For example, if a drug that is
added to a regime reduces fitness of both wildtype and resistant
virus, then it will reduce the probability that a pre-existing resistant
mutant becomes established. This is true even if the effect of the
added drug on wildtype and resistant virus is exactly the same.
Similarly, if the immune system works well, this may also reduce
the probability of establishment.
In most population genetics models, the focus is on the fixation
probability, rather than the establishment probability of a
mutation. And in many models, if a mutation becomes established,
it will go to fixation. However, if selection pressures change,
establishment does not necessarily lead to fixation. This is
especially clear when we will later consider the effect of a single-
dose of nevirapine. A few weeks after a single dose of nevirapine,
nevirapine resistance mutations can be detected in a large
proportion of patients, but these mutations may never take over
the whole viral population, because the treatment duration is very
short and wildtype virus will quickly become a majority again (see
for example, [16]). In fact, the standard results on fixation
probability [32] are really results on establishment probabilities, so
we can use them without problems.
Psgv vs. Pnew
For drug resistance to evolve, the viral population needs viral
particles that carry drug resistance mutations. Such particles may
already be present before treatment is started. To denote this
possibility we use Psgv or the probability that drug resistance
establishes from the standing genetic variation. If the mutation is
not already present, or if was present but was subsequently lost,
then the viral population has to wait for a new mutation to occur
and become established. We denote this possibility as Pnew, or the
probability that resistance evolves due to new mutations. In the
latter case, we have to indicate a time window, such as per year or
per generation.
The goal of this study is to understand and, albeit roughly,
quantify Pnew and Psgv for HIV drug resistance in patients on
triple-drug regimes (consisting of an NNRTI or an unboosted PI
plus two NRTI’s) and in patients who are treated with single dose
nevirapine.
Results
Starting standard therapy
When a patient starts anti-retroviral therapy for the first time,
the viral population in that patient will move from an equilibrium
without drugs to an equilibrium with drugs. At the pre-treatment
equilibrium, the viral population size will at its equilibrium level
(Nu), and resistance mutations are expected to be at mutation-
selection-drift equilibrium, where most mutations will be present at
very low frequencies (see, e.g., [7]). Note that mutation-selection-
drift equilibrium is reached quickly for mutations that are very
costly to the virus. So even though it may take years for neutral
diversity to reach an equilibrium level in an HIV patient [33],
important drug resistance mutations which are 5 or 10% less fit
than the wildtype are expected to reach their (dynamic)
equilibrium in weeks or months.
Standard population genetic theory predicts that the average
frequency of a resistance mutation is equal to the mutation rate (m,
per viral particle and per replication) divided by the relative cost
(Crel) of the resistance mutation, though drift causes actual
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between patients (see also [34]). Even though the average
frequency is independent of the population size, in larger
populations, it is more likely that DRMs are present and the
absolute number of drug resistant particles will, naturally, be
higher. When treatment starts, resistance mutations will confer a
fitness benefit to the virus and they can (but are not guaranteed to)
increase in frequency and become established. The probability
that this happens depends on the number of resistant particles in
the population and on the establishment probability of a mutation
that is present in a single particle. In [14] we derived formulas to
calculate the probability that adaptation to a new environment
happens from the standing genetic variation (Psgv). We will use the
approximate equation 8 in [14]:
Psgv&1{(1z
FmART{1
Crel
)
{2mNu ð2Þ
It is also possible to use the the number of resistant particles in a
patient (B), if this is known, and the fitness of these copies (in the
environment with drugs) to calculate the probability that a
resistance mutation becomes established:
Psgv~1{(1{Pest)
B ð3Þ
where we use the probability that all copies of the resistance
mutation die out to calculate the probability that at least one
survives. The probability that resistance mutations become
established increases with the number of copies of resistant virus
and the probability that any one of these survives.
Evolution of resistance during therapy
If resistance did not evolve from standing genetic variation, it
may evolve due to new mutations. The probability that this
happens in a given year will depend on the number of generations
(G) in a year, the mutation rate (m), the effective population size
during antiretroviral treatment (NART) and the establishment
probability of a mutation (Pest). In principle, the establishment
probability during therapy may not be the same as in the very
beginning of therapy, for example because the number of available
cells which a particle can infect could be different. However,
throughout this paper we will assume that Pest depends only on the
kind of therapy and not on how long a patient has been treated.
Using a poisson approximation, we find that the per year
probability that resistance evolves is
Pnew~1{exp ({GN ART m Pest) ð4Þ
It is debated whether during therapy, there is ongoing
replication or whether a reservoir of latently infected cells is
entirely responsible to residual viremia. If the reservoir reflects the
composition of the viral population before treatment, then the
expected frequency of the resistance mutation in the reservoir
would be
m
Crel. If the number of latently infected cells that become
activated every generation is NLAT, then the expected number of
activated cells with resistant virus would be
NLAT m
Crel . The per year
probability that resistance evolves due to activated cells from the
reservoir would be
Pnew~1{exp (
{GN LAT m Pest
Crel
) ð5Þ
It is also possible that there is ongoing replication, but that the
reservoir also plays a role at the same time, so that the reality will
be reflected best by a combination of equations 4 and 5. Note that
NART and NLAT are both effective population sizes, and may be
much lower than the census population sizes.
Comparison with data and parameter estimation
Published data show that the rate of evolution of drug resistance
is roughly constant over long times (see for example the study by
[3], in which patients were followed for up to eight years). This fits
with expectations if NART and Pest remain constant so that Pnew
stays constant. However, several studies show that the probability
that resistance mutations become established is higher in the first
year of therapy, as compared to later years. This can be seen, for
example, in a study on a large cohort in British Columbia,
especially when one considers the most adherent group of patients
(figure 2 in [35], see also [17]). A similar effect is seen in [11] when
one considers the patients with pre-existing DRMs. This effect,
that resistance is more likely to evolve in the first year of therapy as
compared to later years, can be easily explained by standing
genetic variation.
Under the assumption that Pnew is indeed constant, we can use
published data to estimate both Pnew and Psgv. Margot et al [36]
reported the number of patients in which resistance was detected
in the first, second and third year after treatment initiation in a
cohort of patients who were treated with NNRTI-based ART.
The reported data (see table S1 in supplementary text S2) show
that the probability that resistance was detected in the first year
was 9.5%, whereas in the second and third year it was only 3.7%
(see supplementary material for details on how this was estimated).
The difference of 5.8% is likely due to standing genetic variation at
the start of therapy.
We will use the estimates for Pnew (0.037 per year) and Psgv
(0.058) from [36], in combination with other, published, estimates
to get a rough estimate of the important evolutionary parameters.
First of all, we will assume that the mutation rate from one
nucleotide to a specific other nucleotide is 10{5 [37], so that if
there are five main resistance mutations for a given drug
combination, the total mutation rate is approximately 5|10{5.
For the remainder of the paper, we will only use this total mutation
rate. If the mutation rate would be higher (lower) than our
assumption, the estimated population sizes would be lower (higher)
than our estimates. An overview of the parameter values we use in
the paper is given in table 2.
We know that the important drug resistance mutations are at
least somewhat costly for the virus. Their cost, Crel, has been
estimated for several drug resistance mutations, both in vivo and in
vitro (for an overview on resistance mutations in the reverse
transcriptase gene see [38]). For example, [39] find that the
relative cost of resistance mutation M184V is approximately
0:04{0:08. Wang et al [40] estimate a cost of 0:01{0:04 for
K103N, which is the most common NNRTI resistance mutation.
Other studies were not able to detect any cost of K103N, but given
its low frequency in untreated patients [7], it seems likely that it is
associated with a significant cost. In this paper we will use an
average cost of 0:05 for all mutations.
Given the cost, the mutation rate, Psgv and Pnew, and using the
assumption that there are 200 HIV generations in a year [41], we
can find the combinations of Nu, NART and FmART that are
compatible with the data (shown in figure 1). Estimates for the
effective population size in untreated patients range from 103 [42]
to 105 [43]. We know that a large proportion of untreated patients
carries low frequency drug resistance mutations, but not all
patients, which gives us some additional information about the
Standing Variation and Drug Resistance in HIV
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a value of Nu of 2|103, then we find that about half of the
patients should carry pre-existing DRMs. This is somewhat higher
than what is usually detected, but that can be due in part to the
limits of detection of current tests [8]. An overview of the
parameter estimates that were used in the simulations and for
analytical predictions can be found in table 2.
Given our choice of Nu, we find that FmART must be
approximately 1:017, leading to Pest&0:034. Under the assump-
tion Pest stays the same during treatment, the Margot et al data are
compatible with a 18-fold reduction of the effective population size
due to therapy, to an effective population size of NART&108 .
Note however, that the estimate of a 18-fold reduction depends
heavily on the assumption that Crel~0:05 . For example, had we
assumed a 10% cost, then the estimated reduction would have
been 37-fold , and for a 1% cost, the reduction would have been
only 4-fold . The reason is that if we assume that costs are high,
then we must also assume that the mutant fitness (FmART)i s
relatively high, in order to find Psgv~0:06, and if FmART is high,
NART must be low, to explain Pnew~0:037.
If the evolution of resistance during therapy is not due to
ongoing replication, but due to continuous activation of latent
cells, then, under the assumption that Crel~0:05, the effective
number of cells (NLAT) must be approximately 5 per generation.
This means a reduction of effective population size of almost 400-
fold. However, it is not so clear whether in this case the word
‘‘population size’’ should still be used, because the number 5 is not
an estimate of the size of the reservoir, but an estimate of the
effective size of the part of the reservoir that is reactivated every
generation.
The result that the frequency of resistance mutations in the
reservoir depends on their fitness cost (
m
Crel), whereas the cost does
not play a role for new mutations due to ongoing replication, could
be harnessed to estimate the relative importance of the reservoir. If
the reservoir is the most important source of resistance mutations
during therapy, then the same set of mutations should be found in
patients whose virus acquires resistance quickly after the start of
therapy and in those who acquire mutations during therapy.
However, if ongoing replication is the source of resistance
mutations during therapy, then mutations with a high cost in
the absence of drugs should occur relatively more often during
therapy than quickly after therapy is started.
The data and the results from simulations and predictions (using
equations 2 and 4) are shown in figure 2. The percentage of
patients with resistance after one year is lower in the simulations
than in the analytical predictions, because in the simulations, it
takes time for a mutation to increase in frequency and be detected.
We assume that it is detected as soon as it is more frequent than
the wildtype, the result is that in the simulations (and probably in
reality) Pnew is lower in the first year than in the other two years. It
is unclear how large this effect is in reality, but it means that the
6% we find is a conservative estimate of the role of standing
genetic variation. If it would take 3 months for a mutation to
increase in frequency and become detected, then Pnew in year 1
would be 75% of its value in the later years, and Psgv would be
approximately 7% in stead of 6%.
Single-dose nevirapine for prevention of
mother-to-child-transmission
A single dose of nevirapine (sdNVP) just before labor starts
reduces the risk that a mother transmits HIV to her baby at birth,
but leads to high levels of resistance in many women. Because of
the long half life of nevirapine, even a single dose lasts at least a
few days. However, this is a very short amount of time (only a few
HIV generations) so that probably most or all detected NVP
resistance mutations are due to standing genetic variation.
Because it is known that sdNVP can lead to the establishment of
resistance mutations, and also to further reduce the risk that the
baby becomes infected with HIV, several different treatment
strategies are being used. In this study, we focus only on those
strategies that include a single dose of nevirapine (and exclude, for
example, pregnancy limited triple-drug therapy). Basically, sdNVP
can be combined with either a short course of zidovudine
monotherapy during the third trimester of pregnancy (ZDV/
sdNVP), or it can be combined with additional drugs during and
after labor up to one month postpartum (sdNVP/PP). It can also
be used alone (sdNVP) or combined with both (ZDV/sdNVP/PP),
resulting in four possible strategies.
Under the assumption that all resistance is due to standing
genetic variation, it is straightforward to predict, at least
qualitatively, the effect of the four treatment options. Single dose
nevirapine plus two additional drugs (sdNVP/PP) is a three drug
regimen, and similar to standard antiretroviral therapy (ART),
except that it only lasts a few days or weeks. We therefore expect
similar levels of drug resistance due to standing genetic variation.
If only NVP resistance is considered (and not resistance to the
other two drugs), we expect to find somewhat lower levels than in
the normal case, although the difference may not be large because
resistance against NVP is more common than resistance to most
other drugs. Treating with only sdNVP is different from starting
ART, in that there is only one drug. The result is that the fitness of
both wildtype and resistant virus will not be reduced as much as in
the normal case. Specifically, NVP resistant virus will have a
relatively high fitness during NVP monotherapy. This high fitness
(FmNVP) leads to a high establishment probability (Pest) for
available resistance mutations. In fact, the establishment proba-
bility may be so high that in virtually all patients that carry some
Figure 1. Probability of detecting resistance per year of
treatment. The probability that resistance is detected for the first
time in the first, second or third year of treatment, given that it was not
detected until then. Grey bars are the estimates from the Margot et al
([36]) dataset, and the number of patients on which the estimates are
based are noted at the top of the graph. The red dashed area reflects
the inferred probability that resistance mutations from standing genetic
variation become established. The black squares are values calculated
using equations 2 and 4. The red circles are estimated from 1000
simulations. Parameters as in table 2.
doi:10.1371/journal.pcbi.1002527.g001
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frequency during NVP treatment.
An interesting treatment option is to start with a few weeks of
ZDV monotherapy before treating with a single dose of
nevirapine. The ZDV treatment will reduce the population size
of the virus, Nu, so that the probability that NVP resistance is
available and the copy number of such resistant mutants if they are
available will be lower by the time the patient is treated with NVP.
ZDV monotherapy ultimately leads to ZDV resistance, but the
risk that resistance mutations become established during a short
course is small. ZDV monotherapy reduces the viral load
approximately three-fold [44]. Finally, adding ZDV treatment
before labor and two additional drugs during and after labor
(ZDV/sdNVP/PP) will reduce both the availability of NVP
resistant virus and the establishment probability of such virus,
which should lead to an even lower probability that NVP
resistance mutations from standing genetic variation become
established.
Comparison with data for single dose nevirapine
We identified 23 published studies that reported on NVP
resistance 6 to 8 weeks after women were treated with sdNVP.
Several of the studies directly compared two different treatment
options. We found at least three studies for each of the four
different treatment options. An overview of the studies can be
found in table S2 in the supplementary text S2. For each study we
recorded which of the four treatment options was used and in how
many of the patients NVP resistance mutations were detected
using simple Sanger (population) sequencing (we excluded studies
that only recorded deep-sequencing or allele-specific PCR results,
as there were too few of those to allow us to compare the treatment
options). For each of the four treatment options, we also calculated
the overall probability that resistance mutations were detected in a
patient (simply by summing the number of patients with resistance
and summing the total number of patients in the studies). We
found that sdNVP leads to detectable resistance mutations in 39%
of 952 patients, ZDV/sdNVP leads to detectable resistance
mutations in 22% of 888 patients, adding two drugs during and
after labor (sdNVP/PP) lead to detectable resistance mutations in
7.8% of 372 patients and ZDV/sdNVP/PP lead to detectable
resistance mutations in none of 292 patients (see figure 3).
We now used these data, in combination with our previous
parameter estimates, to estimate the fitness of a NVP resistant
mutant during NVP therapy (FmNVP) and the reduction of the
population size due to ZDV treatment (NZDV). We find that
FmNVP&1:54 and that ZDV reduces the effective population size
approximately two-fold (table 2 and figure 4). The results show
that a reduction in population size by ZDV monotherapy does
reduce the probability that NVP resistance mutations become
established, but adding two drugs to sdNVP helps much more. We
also estimate the fitness of the mutant during therapy with
nevirapine and two additional drugs and find a slightly higher
value than our previous estimate (1:025 vs 1:017), though these
differences are not statistically significant.
Interruption of therapy
During a treatment interruption, drugs are first removed from
the body, which can take from a couple of hours to a several days
or even weeks ([45,46,47]. With some delay, depending on the
half-life of the drugs, the viral population begins to grow, which is
observed as an increase of viral load (see figure 5). Published data
show that after treatment is stopped, viral load quickly increases in
almost all patients (e.g., [2]. Davey et al [31] show that average
viral load plateaus four weeks after treatment is interrupted.
Garcia et al [48] and Trkola et al ([49]) both report that a plateau
is reached between four and eight weeks after treatment
interruptions. An interruption is ended when treatment is started
again and viral load goes down, hopefully to undetectable levels.
Figure 1 shows a cartoon of the pharmacodynamics and
population dynamics of a treatment interruption.
Restarting therapy
If the length of a treatment interruption is so long that the
population size is back to pretreatment level and mutation-
selection-drift equilibrium is again reached, the probability that
resistance mutations become established when therapy is started
again will equal the probability that resistance mutations become
established the first time a patient starts treatment, Psgv from
equation 2. But if a treatment interruption is shorter than that, it is
Figure 2. Possible combinations of population size and fitness
and the effect of population sizes on the probability that DRMs
are present before treatment. Figure 2a: Continuous line:
combinations of population size before treatment (Nu) and fitness of
mutant virus during therapy (FmART) that lead to the observed
probability that resistance mutations from standing genetic variation
become established (Psgv~0:058). Dashed line: combinations of
population size during treatment (NART) and fitness of mutant virus
during therapy (FmART) that lead to the observed probability that
resistance mutations from standing genetic variation become estab-
lished (Psgv~0:058). Open dot: Nu~2000 and FmART~1:017, closed
dot: NART~108, FmART~1:017. Figure 2b: Probability that a patient
has any pre-existing DRMs before the start of therapy for different
population sizes, and m~5|10{5. Open dot: Nu~2000.
doi:10.1371/journal.pcbi.1002527.g002
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upon re-initiation of therapy because neither population-dynamic,
nor population-genetic equilibrium will have been reached. The
absence of the population-genetic equilibrium is most problematic
if resistance mutations are not very costly to the virus. However,
for a costly mutation it takes only on the order of 1=Crel
generations to reach mutation-selection-drift equilibrium. The
absence of population-dynamic equilibrium is less problematic,
because it is relatively easy to predict the population size of the
virus or to measure viral load. In the simulations, we allow the
population to grow exponentially until it reaches the baseline level.
The resulting population size can be plugged into equation 2 to get
an estimate of the probability that resistance mutations become
established due to a treatment interruption.
Comparison with data for treatment interruptions
Using the parameter values from the last two sections, we can
predict the risk that resistance mutations become established due
to a treatment interruption of a certain length. We use the
estimated fitness of the mutant virus during NVP therapy, and
assume that the fitness of the mutant in absence of drugs is the
same. With that value, we can calculate the fitness of the wildtype
in the absence of drugs, because of the assumption that the cost of
the resistance mutation is 5%. The wildtype fitness will determine
how fast the virus grows in the simulations after treatment is
interrupted, and therefore how long it takes before the population
size is back at the pretreatment level. Specifically, we use
Fwt~1:62. In the simulations, the population size plateaus after
just 14 days, but Psgv reaches its expected value only after 60 days
(figure 6).
We collected information from structured treatment interrup-
tion trials to test the predictions. The probability that resistance
mutations become established due to a single treatment interrup-
tion was estimated for seven clinical trials with different lengths of
treatment interruptions [50,22,51,52,53,54,20]. An overview of
the trials can be found in table S3 in text S2 (supplementary
material). We first calculated the risk under the assumption that all
observed resistance was due to treatment interruptions and then
subtracted the estimated probability that resistance mutations
become established during therapy. The corrected values are
shown in figure 6. The data show that longer treatment
interruptions indeed lead to a higher risk of resistance. The risk
plateaus around 37 days, which is consistent with the time it takes
for viral load to reach its equilibrium level (although the
simulations suggest that the risk should plateau later than the
population size). The highest risk was found to be approximately
6% per interruption, just like the risk of starting therapy for the
first time.
Discussion
The main aim of our study was to understand and quantify the
importance of standing genetic variation for the evolution of drug
resistance in HIV. We find that the probability that at least one
resistance mutation becomes established due to standing genetic
variation (Psgv) depends on the kind of treatment chosen. Most
clearly, it is much higher when treatment is with sdNVP (which is
monotherapy) than if treatment is with triple-drug combination
therapy. For standard combination therapy (ART), we use two
different data sources to estimate the probability that resistance
mutations from standing genetic variation become established. In
the first part of this paper we used data on the number of patients
in which resistance was detected in the first year of treatment
versus later years. In the third part of this paper we used data from
clinical trials on treatment interruptions. In both cases, we found
that the probability that resistance mutations from standing
genetic variation became established was approximately 6%.
The importance of new mutations as compared to pre-existing
mutations could be estimated from the Margot et al ([36]) study.
We estimated that the probability that a resistance mutation
becomes established during therapy (Pnew) is 3.7% per year, which
means that pre-existing mutations and new mutations are equally
important after about one-and-a-half year of treatment. Two of
the interruption studies also provided estimates for Pnew, which
were slightly higher (4.3% and 4.8% per year) than the estimate
from the Margot et al [36] study (see table S3 in text S2). It is likely
that some of the patients in these studies were not perfectly
adherent to treatment, so that our estimate of Pnew is inflated by
patients who interrupted treatment. This does not affect our
estimates of Psgv. However, it means that the relative importance
of pre-existing mutations is highest in completely adherent patients
(because new mutations are relatively unimportant for them) and
lower in non-adherent patients (see [7] but see [11]).
A stochastic model was used to understand the effect of standing
genetic variation on the evolution of drug resistance during HIV
treatment. Four parameters are crucial to understand the role of
standing genetic variation. Three of them determine the amount
of genetic variation that is available (effective population size,
mutation rate and cost of the resistance mutations) and one
determines how likely it is that the available mutations become
established (the absolute fitness of the resistant virus during
treatment).
The cost and the mutation rate are parameters that are different
for each specific mutation. Together, they determine the expected
frequency of the mutant in an untreated patient. For example, in
untreated patients the frequency of K103N was found to be lower
Figure 3. The probability that resistance mutations are
detected in women treated for prevention of mother-to-child
transmission. The probability that resistance mutations are detected 6
to 8 weeks after treatment with single dose nevirapine. Black crosses
are data from single studies, grey bars with estimated standard error are
percentages for all studies combined (the number of patients that were
used to calculate this percentage is indicated at the top of the graph).
Red circles with standard error are results from 1000 simulations and
the black squares are analytical predictions. Parameter values as in
table 2.
doi:10.1371/journal.pcbi.1002527.g003
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for K103N. The costs for some of the most important mutations
(M184V, K103N) have been estimated and are between 1 and
10% ([38,39,40]. Throughout this paper we used a value of 5%.
The effective population size in an untreated patient (Nu)
determines how much variation there is in the frequency of
resistant mutants between patients. If Nuw1=m, the frequency in
each patient will be very close to the expectation, m=Crel, but if
Nuv1=m, there will be a lot of variation between patients, and in
many patients no resistance mutations may be available at all.
Data suggest that in HIV the latter is the case (e.g., [7]), which
means that, not every single point mutation is created every
generation in an HIV patient. Or, more precisely, each mutation
may be created, but not in a viral particle that is part of the
effective population size. Mutations may even be detected in the
blood stream of a patient, but may still be irrelevant if the viral
particles with the mutations are eliminated before they can infect a
CD4 cell. Nu also determines the number of resistant viral particles
in a patient with a given frequency of the mutant. With higher Nu,
there will be a higher number of resistant particles, and this makes
it more likely that resistance mutations become established when
treatment is started [11].
We find that data are compatible with an 18-fold reduction of N
due to ART and a two-fold reduction of N due to ZDV
monotherapy. The estimated reduction depends on the assumed
cost of mutations; if we assume that mutations are twice as costly,
we would find a reduction that is twice as severe. Still, the
reductions we find are not nearly as severe as one may have
expected based on viral load reductions. During ART, VL may be
reduced 1000-fold or more (in the Margot ([36]) study from which
we used the data, patients had a viral load of, on average, 8|104
before treatment, whereas after 48 weeks of treatment, about 80%
of the patients had a viral load of less than 50, [55]). This
discrepancy may be due to two effects: firstly, our estimate is an
average for many patients and this average may be driven up by
patients in which the drugs do not work well, or who are not
adherent to therapy so that their VL does not go down as much as
expected. Secondly, the relationship between effective population
size and viral load may not be linear, so that a thousand-fold
reduction in VL may translate in only a twenty-fold reduction in
effective population size.
The fourth important parameter is the fitness of the mutant
virus during treatment (Fm), which determines the establishment
probability (Pest).Fm will depend on both the drugs that are used
and on the specific mutation. For example, the resistance mutation
K103N is more likely to become established during sdNVP than
during triple-drug therapy, because additional drugs reduce Fm
(FmARTvFmNVP). And during triple-drug therapy, K103N is
more likely to become established than Y181C (even though
Y181C is present at higher frequencies before treatment), likely
because FmART is higher for K103N than for Y181C.
Starting of standard therapy
We assumed that the rate of evolution due to new mutations is
constant and that the establishment of a resistance mutation from
standing genetic variation leads to viral failure and is detected
within one year of starting therapy. Maybe the most convincing
evidence for these assumptions comes from the Li et al [11] study,
Figure 4. Probability of the establishment of DRMs as a function of effective population size and the fitness of the resistant mutant
during treatment. The predicted probability of the establishment of drug resistance mutations from standing genetic variation depending on the
effective population size and the fitness of the resistant mutant during therapy. Grey scales indicate the probability of the evolution of drug
resistance due to standing genetic variation. Dots indicate estimated parameter combinations for treatment with just sdNVP, with ZDV monotherapy
followed by sdNVP (ZDV/sdNVP), with sdNVP followed by two additional drugs postpartum (sdNVP/PP) and with ZDV monotherapy followed by
sdNVP and two additional drugs postpartum ZDV/sdNVP/PP.
doi:10.1371/journal.pcbi.1002527.g004
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existing DRMs show a constant rate of evolution of resistance and
(2) patients with detected pre-existing DRMs show an increased
rate compared to the patients without pre-existing DRMs, but
only in the first year of treatment. We used these assumptions to
estimate the probability that resistance mutations from standing
genetic variation become established. However, the estimated role
of standing genetic variation may be a slight underestimate,
because establishment of new mutations should need some time so
that Pnew would normally be somewhat lower in the first year of
treatment. The observation that the effect of standing genetic
variation only lasts a year, means that fixation of a resistance
mutation must take less than a year. This limits possible values for
NART and FmART to such values for which the fixation time is less
than 200 generations.
If resistance indeed evolves due to standing genetic variation in
6% of patients on standard ART, then there is clearly room for
improvement. Note that those 6% of patients have already lost
their first treatment option shortly after having started treatment.
They have to switch to second-line treatment which is more
expensive, usually more complicated (more pills per day) and likely
has more side effects. It is therefore worth exploring ways to avoid
the establishment of resistance mutations from standing genetic
variation. Figure S2 suggests two options to reduce Psgv,b y
reducing the population size or by reducing the fitness of the
resistant mutants. The first may be achieved by ZDV monother-
apy, as shown in the section on PMTCT, whereas the second may
be achieved by adding additional drugs to the treatment.
Obviously, triple-drug combination treatment is already standard
for most HIV patients, but it may be worth considering specifically
which treatment options would be best to prevent the evolution of
resistance from standing genetic variation. This may mean, for
example, to add a fourth drug to the therapy in the first couple of
weeks of treatment. Resistance to boosted PI’s is very uncommon,
so they may be a good choice for starting treatment, in
combination with two or three other drugs.
Resistance due to sdNVP
Studying treatment with a single dose of nevirapine gives us a
unique opportunity to study the effect of standing genetic
variation, because treatment is so short (only a few HIV
generations) that we can assume that most or all resistance
mutations that are detected are from standing genetic variation.
Data show that the risk that resistance mutations become
established due to such treatment is very high (39%). We find
that this high probability can be explained entirely by selection on
pre-existing drug resistance mutations, because the fitness of NVP
resistant virus is probably very high during NVP monotherapy.
We estimate that its fitness is approximately 1.5. The probability
that a resistance mutation becomes established can be reduced by
either adding additional drugs to lower the fitness or by lowering
the population size so that fewer mutants are available. A study
from Zambia [56] showed that the additional drugs even help to
reduce the establishment of NVP resistance mutations consider-
ably if the additional drugs are given as a single dose (in stead of
treatment for a couple of days or weeks). We did not include this
study in the overview, because there was only one study that
looked at this treatment option.
The results on ZDV/sdNVP/PP treatment (i.e., treatment with
ZDV during pregnancy and NVP plus two other drugs during
labor) are surprising in that NVP resistance mutations were not
detected in any of the women who received this treatment, even
though the model would predict that mutations would be detected
in 4% of the women. Most of the data on this treatment option are
from the Lallemant [57] paper (222 women). In this study, the
authors do find some mutations that confer resistance to the
NRTI’s in the study (in 2.3% of the women). The same study also
looked at women who were treated with ZDV/sdNVP and also in
these women the percentage with resistance mutations was very
low (6.4%) and much lower than the mean value for women who
receive this treatment (22%). The reason for the surprisingly low
values of drug resistance in this study could be that the women in
the study had very low viral loads (median 2800). This probably
also means that they have a low effective population size. It
therefore seems unlikely that the extremely good results from the
Lallemant study [57] can be replicated in other populations.
However their results still show that using additional drugs to
reduce the population size and to reduce the fitness of the mutant
may be a good strategy to reduce the probability that resistance
becomes established.
Treatment interruptions
Considering treatment interruptions, our model provides several
testable predictions. 1) resistance mutations are more likely to
become established after long treatment interruptions when viral
loads are higher, 2) the risk that resistance mutations become
established due to a treatment interruption can not be larger than
the risk at the start of treatment, 3) treatment interruptions
Figure 5. Drug level and population size during and after a
treatment interruption. Drug level (dashed line) and viral population
size (solid line) during and after a treatment interruption. Red bars
indicate when drugs are taken.
doi:10.1371/journal.pcbi.1002527.g005
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drugs with short half-lifes.
Data from seven clinical trials show that indeed, longer
interruptions increase the probability that resistance mutations
become established (figure 6). Moreover, the estimated probability
appears to plateau after 37 days, which is similar to the time it
takes for viral load to reach its pretreatment level. This suggests
that the risk of establishment of resistance mutations is directly
linked to the viral load when treatment is started again. The
second prediction was also found to hold: the estimated risk that
resistance mutations from standing genetic variation become
established at the start of treatment was found to be similar to the
risk due to a long treatment interruption (6% in both cases). The
third prediction also holds, as data show that interruptions
increase the risk of establishment of resistance mutations even
for PI based treatment [20,51], where the ‘‘tail of monotherapy’’
cannot explain the observations.
A potential problem with the data is that not only the length of
the interruptions, but also the length of treatment periods between
the interruptions differed between the seven studies. The trials that
were compared also differed in the drugs that were used (see table
S3 in text S2), which makes direct comparison difficult. Despite all
these limitations, it becomes clear that longer interruptions carry a
higher risk of evolution of resistance than shorter interruptions.
If interruptions lead to the establishment of resistance mutations
only due to the ‘‘tail of monotherapy’’, as is usually assumed in the
HIV literature [24,25,18], we would predict that: 4) treatment
interruptions increase the risk that resistance mutations become
established only for drugs with long half-lifes, 5) the risk that
resistance mutations become established due to a treatment
interruption is unrelated to the risk at the start of treatment and 6)
the largest risk would be due to an interruption with a length that
is exactly the time it takes for the last drug to lose its effect on the
wildtype virus. All of these predictions do not hold. This is not to
say that the ‘‘tail of monotherapy’’ is not important at all. But it
does show that on its own, the ‘‘tail of monotherapy’’ cannot
explain the risk that resistance mutations become established due
to treatment interruptions. When one considers possible interven-
tion strategies, this may be good news. If treatment interruptions
are risky because of restarting rather than stopping therapy, this
would give doctors a possibility to reduce the risk that resistance
mutations become established even after a patient has already
stopped taking his or her drugs. The establishment of resistance
mutations at re-initiation of treatment may be avoided by
pretreatment (such as with ZDV) to reduce the availability of
mutations or by using more drugs or higher doses in the first weeks
of treatment to reduced the establishment of pre-existing
mutations.
General remarks
We have used a population-dynamic and population-genetic
model to study several patterns of drug resistance in HIV. The
model explains why resistance mutations are likely to become
established in the first year of standard treatment, in women who
are treated with a single dose of nevirapine and in patients who
interrupt treatment. In all three cases, standing genetic variation
can explain the observations.
Our results illustrate that for adaptive evolution to happen,
selection and the creation of new variation need not happen at the
same time, if selection can work on standing genetic variation. In
Figure 6. The relationship between the length of a treatment interruption and the probability that DRMs become established.
Estimated probability that resistance mutations become established due to a single treatment interruption. Grey bars are data from seven clinical
trials, z={ estimated standard error (see supplementary table S3 in text S2). The number of patients (and the number of interruptions per patient)
are noted at the top of the graph. The red circles are estimated from 1000 simulations, z={ estimated standard error. The black squares are
predictions using the average population size from the simulations and equation 2. Parameters as in table 2.
doi:10.1371/journal.pcbi.1002527.g006
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drug levels (which allow for replication and selection at the same
time) are not a necessary condition for the evolution of drug
resistance. This result about time-heterogeneous drug levels is
similar to the result on heterogeneity in space by Kepler and
Perelson [58], who showed that genetic variation may be created
in compartments where drugs cannot penetrate whereas selection
happens in other compartments.
Our model provides a simple and quantitative explanation for
why resistance is less likely to evolve when patients are treated with
multiple drugs in stead of just one drug. Additional drugs reduce
the fitness of a mutant that is resistant against one drug, and
therefore the establishment probability of such a resistant mutant.
In addition, additional drugs reduce the population size of the
virus and thereby the creation of new resistance mutations. This
means that there will be fewer resistance mutations with lower
establishment probabilities, together leading to a strong reduction
in the probability that resistance evolves. In newer therapies with
boosted PIs, drug resistance has become very rare [3], which may
be because boosted PIs are so strong that no single mutation can
lift the virus’ fitness above 1.
The model in this study may be relevant to other diseases than
HIV. For example, the evolution of resistance is a problem in
chronic myeloid leukemia (CML) which is a cancer of white blood
cells. A recent study suggested that the probability that drug
resistance evolves in CML goes down with time because the
population size of the cancer goes down with time [59].
Resistance is also a problem in tuberculosis (TB), and in TB it is
also known that treatment interruptions increase the risk of
evolution of resistance [60]. This effect may also be due to an
increased population size during the interruptions. In general,
stopping treatment may be risky in cases where treatment has to
be started again, which is always the case for HIV and often for
TB. Each time therapy is started, resistance mutations from
standing genetic variation may become established, and even if
this risk is only a few percent it adds up quickly when patients
interrupt treatment regularly.
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